As investors peer into the future to envision which industries are ripe to be reshaped and energized by artificial intelligence, drug discovery is fast emerging as an obvious choice. Each new drug that hits the market is the product of billions of dollars in investment, often taking at least a …
Eli Lilly ‘s raised guidance stole the show Tuesday, offsetting mixed first-quarter results and propelling shares higher by nearly 6%. The numbers leave little doubt that the long-term Eli Lilly success story remains intact, as demand for its new diabetes and obesity drugs, Mounjaro and Zepbound, outstrips supply. Revenue in …
Stocks that have been under pressure this week could be primed for a rebound. The major averages rose on Friday, attempting a comeback from the prior session’s losses and the Dow Jones Industrial Average’s worst day since March 2023. Despite the recovery attempt, all three indexes are tracking for a …
